AstraZeneca sets $80 billion revenue target by 2030
Company aims to launch 20 new medicines by 2030, and reduce carbon emissions
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
oncology
Alembic Pharmaceuticals receives an EIR for its oncology formulation facility
According to the company’s statement, all EIRs are in place for their USFDA facilities
Zydus launches IBYRA, the generic version of Olaparib
The drug will target specific genetic mutations prevalent in certain types of cancers
Oncology dominates CRISPR landscape: GlobalData
Oncology accounts for 30 per cent of all active CRISPR drugs
Colorectal cancer market across 8MM to reach $21.8 bn in 2031: GlobalData
This uptrend is primarily driven by rising diagnosis rates, notably in key markets like the US and China and approvals of 13…
Merck seeks to develop novel T-cell engager therapies with TriTAC platform: GlobalData
The deal includes the novel HPN-217 and HPN-328 compounds, which are currently undergoing Phase II clinical trials for various…
Parexel and JFCR collaborate for cancer research
Under the agreement, JFCR will join Parexel’s Global Site Alliance network for oncology clinical trials and providing more…
AstraZeneca shares data from HIMALAYA, MATTERHORN Phase III studies at ESMO Asia Congress 2023
The International Agency for Research on Cancer (IARC) forecasts a 58 per cent surge in GI cancer cases by 2040 globally
First-in-class DLL3-targeting BiTE could be the next big player in SCLC treatment: GlobalData
The drug is forecast to achieve peak sales of $788 million by 2029
DCGI approves KEYTRUDA to treat triple negative breast cancer, renal cell carcinoma
KEYTRUDA is now approved for 14 indications across eight tumour types in India